Purchase this article with an account.
MP Hatton, MS Gregory, VL Perez, BR Ksander; Rejection of Conjunctival Tumors Using Pro-Inflammatory Signals . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1114.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose:Conjunctival tumors grow within a non-immune privileged ocular site. For this reason, we hypothesize these tumors are highly susceptible to anti-tumor inflammatory responses. In the present series of experiments we attempted to stimulate innate immunity, specifically neutrophils, to eliminate conjunctival tumors. Methods:Lymphoma cells were transfected with cDNA encoding for membrane FasL (mFasL), wild-type FasL (wtFasL), or no FasL. Clones of mFasL tumor cells that expressed low and high levels of mFasL were isolated using limiting dilution techniques. Tumors were injected into the subconjunctival space of syngeneic DBA/2 mice. Tumor growth and survival were recorded. Results:Tumors that express mFasL are capable of directly stimulating neutrophils to de-granulate. To determine if this pro-inflammatory signal could be used to induce rejection of subconjunctival tumors, the following experiments were performed. Syngeneic tumors (FasL negative) grew progressively within the subconjunctival space of DBA/2 mice. By contrast, tumors expressing mFasL were rapidly rejected within the first three days after injection. Tumor rejection occurred regardless of whether high or low levels of mFasL were expressed. Moreover, tumor rejection was rapid, complete, and not associated with non-specific destruction of the surrounding normal conjunctival tissue. Conclusion:Conjunctival tumors grow within a non-immune privileged ocular site and therefore are more susceptible to innate inflammatory responses mediated by neutrophils. Our data imply that membrane FasL can be used to successfully active innate immunity to reject tumors in the conjunctiva.
This PDF is available to Subscribers Only